- Home
- AIM vs MYNZ Comparison
AIM vs MYNZ Comparison
Compare AIM & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIM
- MYNZ
- Stock Information
- Founded
- AIM 1966
- MYNZ 2021
- Country
- AIM United States
- MYNZ Germany
- Employees
- AIM N/A
- MYNZ N/A
- Industry
- AIM Biotechnology: Biological Products (No Diagnostic Substances)
- MYNZ Biotechnology: Pharmaceutical Preparations
- Sector
- AIM Health Care
- MYNZ Health Care
- Exchange
- AIM Nasdaq
- MYNZ Nasdaq
- Market Cap
- AIM 8.8M
- MYNZ 10.5M
- IPO Year
- AIM N/A
- MYNZ 2021
- Fundamental
- Price
- AIM $0.12
- MYNZ $3.44
- Analyst Decision
- AIM Strong Buy
- MYNZ Buy
- Analyst Count
- AIM 2
- MYNZ 3
- Target Price
- AIM $2.75
- MYNZ $14.00
- AVG Volume (30 Days)
- AIM 476.8K
- MYNZ 177.3K
- Earning Date
- AIM 03-27-2025
- MYNZ 04-15-2025
- Dividend Yield
- AIM N/A
- MYNZ N/A
- EPS Growth
- AIM N/A
- MYNZ N/A
- EPS
- AIM N/A
- MYNZ N/A
- Revenue
- AIM $170,000.00
- MYNZ $893,991.00
- Revenue This Year
- AIM N/A
- MYNZ $20.94
- Revenue Next Year
- AIM $1,693.10
- MYNZ $18.01
- P/E Ratio
- AIM N/A
- MYNZ N/A
- Revenue Growth
- AIM N/A
- MYNZ N/A
- 52 Week Low
- AIM $0.11
- MYNZ $0.18
- 52 Week High
- AIM $0.62
- MYNZ $8.20
- Technical
- Relative Strength Index (RSI)
- AIM 42.13
- MYNZ 37.70
- Support Level
- AIM $0.11
- MYNZ $2.72
- Resistance Level
- AIM $0.16
- MYNZ $5.34
- Average True Range (ATR)
- AIM 0.01
- MYNZ 0.55
- MACD
- AIM 0.00
- MYNZ -0.12
- Stochastic Oscillator
- AIM 5.00
- MYNZ 27.48
About AIM AIM ImmunoTech Inc.
AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples.